Glycologix
Beverly, US · Founded 2021 · Delaware corporation · 1 known investors
Find your way into Glycologix
278 people in our graph share verified history with the Glycologix team — schools, employers, funds. One of them is your warm intro.
Aydin Senkutunlockedknows Dan Deardorf · together at The Wharton School (overlapped)
×6knows the team · via The Wharton School
knows the team · via California Polytechnic State University-San Luis Obispo
×2knows the team · via University of Minnesota
knows the team · via University of Massachusetts Amherst
knows the team · via Caltech
Glycologix is a clinical-stage biotechnology company developing locally delivered biopolymers that mimic natural proteoglycans for the protection and repair of soft tissues. Its lead program, GLX-100, targets interstitial cystitis/bladder pain syndrome (IC/BPS), with the technology intended for additional soft tissue indications.
Founders & leadership
Glycologix was founded in 2021 by Thomas Jozefiak.
TJ
Thomas JozefiakinCo-FounderThomas Jozefiak is a co-founder of Glycologix and an R&D consultant with expertise in biomaterials and polymer therapeutics, holding numerous patents and publications in resorbable biomaterials, polymer chemistry, and drug delivery. He has previously co-founded clinical-stage biotechnology companies and held leadership roles in both small and large organizations working on medical devices and drug delivery applications.
DD
Dan DeardorfinCEODan Deardorf is CEO of Glycologix, a clinical-stage biotechnology company developing locally delivered biopolymers for soft tissue protection and repair. He brings over 20 years of biopharma experience in product development, business development, and commercial operations at companies including Genzyme and Flexion Therapeutics, and holds an MBA from Wharton.
RH
Rich HeidebrachtVP, Research + Development
Board
GA
George AdaniyaCo-Founder
MF
Martha FarmerBoard director
MM
Michael MarshBoard director
MC
Michael ChesterBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$5.2M disclosed across 4 rounds · 2021–2025
▶$800KraisedDec 2025 · 30 investors · Other TechnologyRule 506(b)
▶$800KraisedDec 2025 · 30 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- George AdaniyaDirector
- Daniel DeardorfExecutive Officer, Director
- Martha FarmerDirector
- Michael MarshDirector
- Michael ChesterDirector
- Offering amount
- $1M
- Amount sold
- $800K
- Minimum investment
- $1
- Proceeds to insiders
- $250K
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.5MraisedApr 2024 · 48 investors · Other TechnologyRule 506(b)
▶$1.5MraisedApr 2024 · 48 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel DeardorfExecutive Officer, Director
- Douglas SmithExecutive Officer
- Michael MarshDirector
- Michael ChesterDirector
- Martha FarmerDirector
- George AdaniyaDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Minimum investment
- $5K
- Proceeds to insiders
- $200K
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.1MraisedMay 2023 · 25 investors · Other TechnologyRule 506(b)
▶$1.1MraisedMay 2023 · 25 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- George AdaniyaDirector
- Daniel DeardorfExecutive Officer
- Michael ChesterDirector
- Martha FarmerDirector
- Offering amount
- $1.8M
- Amount sold
- $1.1M
- Minimum investment
- $4.9K
- Proceeds to insiders
- $200K
- First sale
- May 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.8MraisedJan 2022 · 28 investors · Other TechnologyRule 506(b)
▶$1.8MraisedJan 2022 · 28 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Michael ChesterDirector
- George AdaniyaDirector
- Daniel DeardorfExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1.8M
- Proceeds to insiders
- $225K
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Abiologics7 shared keywordsAbiologics uses computational design tools to create protein-inspired molecules called Synteins, engineered to avoid the vulnerabilities of natural protein medicines while retaining biological function. The company develops these molecules as a new class of therapeutics with the aim of advancing candidates toward clinical development.
Peptilogics4 shared keywordsPeptilogics is a clinical-stage surgical therapeutics company developing zaloganan (PLG0206), a novel anti-biofilm drug to treat and prevent medical device-related infections such as prosthetic joint infections. Its lead candidate is in a pivotal Phase 2/3 trial and holds FDA Orphan Disease, Fast Track, and QIDP designations.
MediLogix4 shared keywordsMEDILOGIX is a tech-enabled healthcare services platform for medical equipment management, offering rental management, field operations tools, analytics portals, and proprietary products such as CareMatt for care providers. It serves post-acute care facilities in the United States, with software including MxMobile, MxPortal, and its rental-as-a-service (RaaS) offering.
Medlogix4 shared keywordsMedlogix provides end-to-end medical claims management and cost containment solutions for property and casualty insurers, including auto liability, workers' compensation, and personal injury protection. The company serves the top national carriers and regional TPAs through its proprietary MyMedlogix cloud platform, which integrates bill review, utilization review, independent medical examinations, and case management.
Trivascular3 shared keywordsEndologix develops endovascular medical devices for treating vascular conditions such as abdominal aortic aneurysms and peripheral arterial disease in the femoropopliteal arteries. Its stent grafts and revascularization systems are used by physicians performing minimally invasive vascular repair.
Companies competing with Glycologix for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Glycologix do?
- Glycologix is a clinical-stage biotechnology company developing locally delivered biopolymers that mimic natural proteoglycans for the protection and repair of soft tissues. Its lead program, GLX-100, targets interstitial cystitis/bladder pain syndrome (IC/BPS), with the technology intended for additional soft tissue indications.
- Who founded Glycologix?
- Glycologix was founded by Thomas Jozefiak in 2021.
- Who are Glycologix's investors?
- Glycologix's investors include Cortado Ventures.
- How much funding has Glycologix raised?
- Glycologix has disclosed $5.2M raised across 4 rounds.
- Where is Glycologix headquartered?
- Glycologix is headquartered in Beverly, US.